Wed, Jan 22, 2020 · 8:30

The 4th Annual PREDiCT Tumor Models San Francisco Summit 2020 will continue to serve immuno-oncology scientific community, helping you to gain a better understanding of candidate and preclinical profiling through robust selection of models and use of cutting-edge technologies. Explore the opportunities and limitations of syngenic and PDX mouse models, the potential of 3D models and gain a comprehensive understanding of the novelest technologies and imaging techniques that are changing the preclinical and translational field.

This is your ONLY dedicated preclinical model summit that focuses on practical case studies and open collaboration, providing you with unparalled takeaways to accelerate your drug development program.

Make these 3 days the best days in your 2020 calendar – engage with your industry fellow members, exchange learnings and be inspired for a fruitful 2020 program

Brochure: https://go.evvnt.com/526501-3?pid=5731

Price:
Conference + 3 Workshops: USD 3796.0,
Conference + 2 Workshops: USD 3397.0,
Conference + 1 Workshop: USD 2998.0,
Conference Only: USD 2599.0

Speakers: Jaeho Jung, Executive Vice President of R&D, ABL Bio, Shiva Kazerounian, Associate Director of In Vivo, Berg Health, Joshua Breunig, Assistant Professor, Cedars-Sinai, Chung-Wein, Lee Senior Scientist, Celgene Corporation, Amy Wesa, Director of ImmunoOncology Research, Champions Oncology, Erin Riegler, Scientist, Chimera Bioengineering, Dean O Campbell, Director Scientific Engagement Oncology-West, Crown science, Wei Sun, Professor, Drexel University, Keiji Furuuchi Director, Preclinical Development, Epochal Precision Anti-Cancer Therapeutics (EPAT), Eisai, James Keck, Senior Director for the Clinical Lab & In Vivo Pharmacology Services, The Jackson Laboratory, Angus Sinclair, Vice President, IGM Biosciences, Tseten Jamling, VP of Research and Development, Hera BioLabs, Inc, Saad Sirop, Kenderian Senior Associate Consultant - Hematology, Immunology & Molecular Medicine, Mayo Clinic, Gregor Adams, Director of Scientific Development, MI Bioresearch, Jim Hodge, Deputy Chief, Laboratory of Tumor Immunology and Biology Senior Investigator, National Institutes of Health, Kimberly Aardalen, Scientific Technical Leader, Novartis Institutes for Biomedical Research, Loui Madakamutil, Senior Vice President & Head of Discovery & Preclinical Development, Nektar Therapeutics, Daniel Harrington, Assistant Professor, The University of Texas Health Science Center, Pengfei Zhou, Chief Executive Officer, YZY Bio